Arbor Biotechnologies Stock

arbor.bioHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $231.6MM

Arbor Biotechnologies uses AI and machine learning to develop gene editing therapeutics that aim to treat genomic diseases. Their current pipeline focuses on liver and Central Nervous System (CNS) diseases. Arbor Biotechnologies was founded in 2016 by David Scott Ph.D., Winston Yan Ph.D., David Walt Ph.D., and Feng Zhang Ph.D. and is headquartered in Cambridge, MA.

Register To Buy and Sell Shares

For more details on financing and valuation for Arbor Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Arbor Biotechnologies’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Arbor Biotechnologies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

David Cheng
Chief Technology Officer
John Murphy
Chief Scientific Officer
David Scott Ph.D
Co-Founder & Head of Innovation
Winston Yan Ph.D
Co-Founder & Head of Translational Strategy
Devyn Smith Ph.D
Chief Executive Officer & Board Member
Pam Stetkiewicz Ph.D
Chief Operating Officer

Board Members

Chen-Ming Yu MD
TCG Crossover Management
Keith Crandell
ARCH Venture Partners

Arbor Biotechnologies’ stock FAQs


Can you buy Arbor Biotechnologies’ stock?

Arbor Biotechnologies is not publicly traded on NYSE or NASDAQ in the U.S. To buy Arbor Biotechnologies’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Arbor Biotechnologies’ stock?

Yes, you can sell stock of a private company like Arbor Biotechnologies. Forge can help you sell your Arbor Biotechnologies stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Arbor Biotechnologies’ stock price?

Arbor Biotechnologies is a privately held company and therefore does not have a public stock price. However, you may access Arbor Biotechnologies’ private market stock price with Forge Data.

What is Arbor Biotechnologies’ stock ticker symbol?

Arbor Biotechnologies does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Vertex, Arbor Biotechnologies extend agreement on precision gene editing technology

Vertex Pharmaceuticals (NASDAQ:VRTX) and Arbor Biotechnologies have extended a collaboration agreement that will provide the former with rights to the latter's novel precision editing technology for up to three diseases.

After Prime Medicine, What's the Next Gene Editing IPO?

Investors enjoyed a record number of biotech IPOs in 2020 and 2021 as companies raced to grab bags of money from public markets flooded with liquidity. The pipeline has dried up considerably in 2022, primarily due to tightening financial conditions. It's not quite as fun, but it's a sign of healthy markets.

Gene editing advances continue a pace, but progress is still early: panel

With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa (MOTM) say they are looking forward to other near- and longer-term breakthrough technologies on the horizon.
Updated on: Jul 12, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.